Home > Press > Lumera Announces Podcast Interview with CEO Tom Mino as Next in 2007 Lumera Experts Series
Lumera Corporation (NASDAQ:LMRA), a leader in the emerging field of nanotechnology, announced an interview with Lumera Chief Executive Officer, Tom Mino as the most recent installment of its 2007 Lumera Experts Podcasting Series.
Lumera Announces Podcast Interview with CEO Tom Mino as Next in 2007 Lumera Experts Series
BOTHELL, WA | Posted on May 31st, 2007
Mino has helped build Lumera as a leader in light-applied nanotechnology with products serving the bioscience and communications/computing multi-billion dollar industries. As a publicly traded company since 2004, Lumera has raised more than $70 million to date.
"The Lumera Podcasting series continues to be an excellent way for people to learn about the exciting advances in nanotechnology and how it applies to all of us in our lives," said Dr. Hélène Jaillet, Lumera Director of Corporate Communications and Investor Relations. "As a company at the forefront of research and development in the bioscience and telecommunication industries, we are eager to have our CEO share his perspective among the other global experts who have participated in our podcasting series."
"To this point and time, only 20,000 of the 300,000 proteins that exist in the human body have been isolated. Because of the technology that Lumera and others in the field are developing, the next 100,000 proteins may be identified as quickly as were the first 20,000," said Mino in his podcast interview. "This acceleration will have a tremendous impact in drug discovery as the proteins that trigger cancer or diabetes in a cell or weakened heart muscles will now be discovered in a much shorter period of time and have a bigger impact on our quality of life."
Earlier this year, Lumera announced the 2007 Lumera Experts Podcast Series featuring interviews with industry leaders who are familiar with Lumera's technology and are experts in nanotechnology, bio-arrays, drug discovery, electro-optics, and wireless technologies. Podcast interviews by Dr. Niro Ramachandran, a research associate at the Harvard Institute of Proteomics led by Dr. Josh LaBaer, Dr. Larry Dalton, a Professor of Chemistry and Electrical engineering at the University of Washington and Nobel Prize Nominee, and Joseph Vallner, President and CEO of Capnia, have all been previously featured as part of the series and are currently available to download on Lumera's website.
The podcasts are available through a variety of distribution networks and can be downloaded among other places at podtech.com; Apple's iTunes, Rocky Mountain Podcasting and at Lumera's own website, http://www.lumera.com/Company/Podcasts.php .
About Lumera Corporation
Lumera is a leader in the emerging field of nanotechnology. The company designs proprietary molecular structures and polymer compounds for the bioscience and communications/computing industries, both of which represent large market opportunities. The company also has developed proprietary processes for fabricating such devices. For more information, please visit http://www.lumera.com .
Certain statements contained in this release are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products; and other risk factors identified from time to time in the company's SEC reports, including its Annual Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
For more information, please click here
Dr. Helene Jaillet, 425-398-6546
The Summit Group Communications
Todd Wolfenbarger, 801-595-1155
Copyright © Business Wire 2007
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015
'Bulletproof' battery: Kevlar membrane for safer, thinner lithium rechargeables January 28th, 2015
Spider electro-combs its sticky nano-filaments January 28th, 2015